EUCTR2008-001535-35-FR进行中（未招募）不适用
A Phase 1b/2 Study of Gemcitabine-Cisplatin, With or Without LY2275796 Sodium, in Patients with Advanced Stage IIIB or IV Non-Small Cell Lung Cancer - N/A
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible to be included in the study only if they meet all of the following criteria:
- •[1] Histologically or cytologically confirmed diagnosis of NSCLC.
- •[2] Stage IIIB (N3 and/or pleural or pericardial effusion) or IV disease that is not amenable to either surgery of curative intent or radiation therapy. Refer to Protocol Attachment JKAH.4., American Joint Committee on Cancer Staging Criteria for Lung Cancer (Fleming et al. 1997).
- •[3] All of the following if patient has had prior radiation therapy:
- •Lesion(s) used for determination of response were not previously irradiated or have increased in size since the completion of radiotherapy.
- •Patient has fully recovered from any toxicity of the radiotherapy.
- •Radiotherapy was completed at least 2 weeks prior to enrollment.
- •[4] Have measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan, OR nonmeasurable disease (Part 1 only), defined according to RECIST (refer to Protocol Attachment JKAH.5.)
- •[5] Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (refer to Protocol Attachment JKAH.6).
- •[6] Have an estimated life expectancy of at least 12 weeks.
- •[7] Adequate organ function, including the following:
- •Hematologic: Absolute neutrophil count (ANC) 1.5 109/L, platelets ?100 ? 109/L, and hemoglobin ?9 g/dL (?5.6 mmol/L). Patients may receive erythrocyte transfusion to achieve this hemoglobin level at the discretion of the investigator.
- •Hepatic: Bilirubin ?1.5 times the upper limit of normal (ULN), alkaline phosphatase (AP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ?3.0 ? ULN.
- •Renal: Calculated creatinine clearance ?60 mL/min per Cockcroft and Gault formula (refer to Protocol Attachment JKAH.7) (Cockcroft and Gault 1976).
- •[8] For Part 1: Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 4 weeks (6 weeks for mitomycin-C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy.
- •[9] Patient compliance and geographic proximity (investigator’s discretion) that allows adequate follow-up.
- •[10] Must sign an informed consent document (or legal representative has given informed consent).
- •[11] Males or females of at least 18 years of age.
- •[12] Females of child-bearing potential (not surgically sterilized and between menarche and 1 year post menopause) must test negative for pregnancy within 7 days prior to or at the time of enrollment based on a serum pregnancy test. Both males and females of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and his or her health care team, during the study and for 6 months following the last dose of study treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •[13] Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •[14] Part 1: More than 2 prior chemotherapy or biological therapy (approved or experimental) for NSCLC, not including adjuvant and neoadjuvant treatment.
- •Part 2: Prior chemotherapy or biological therapy (approved or experimental) for NSCLC, including adjuvant and neo-adjuvant treatment.
- •[15] Inability to undergo hydration/diuresis (per investigator’s discretion) for cisplatin administration.
- •[16] Have documented brain metastases unless the patient has completed successful local therapy for central nervous system metastases and has been off of corticosteroids for at least 4 weeks before enrollment. Brain imaging is required in symptomatic patients to rule out brain metastases, but is not required in asymptomatic patients.
- •[17] Have active infection or serious concomitant systemic disorder (for example, heart failure) incompatible with the study (at the discretion of the investigator).
- •[18] Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
- •[19] Have bleeding diatheses.
- •[20] Peripheral neuropathy, CTCAE ?Grade 2 (Cancer Therapy Evaluation Program 2003).
- •[21] Patients eligible for combined modality therapy as defined by the combination of chemotherapy, radiation therapy, and/or surgery.
- •[22] Have known hypersensitivity to oligonucleotides or any component of the formulation.
- •[23] Concurrent treatment with other anti-cancer drugs.
研究者
相似试验
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-FRsanofi-aventis recherche & développement105
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-DEsanofi-aventis recherche & développement
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IVMedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017270-21-ITsanofi-aventis recherche & de'veloppement105
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-GBsanofi-aventis recherche & développement105
已完成
1 期
Phase I/II study of gemcitabine/cisplatin/S-1(GCS) combination therapy for patients with advanced biliary tract cancerPatients with advanced biliary tract cancer that was not amenable to potentially curative surgery or that had recurred after surgeryJPRN-UMIN000004468Kansai Hepatobiliary Oncology Group55